Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Rocket Pharmaceuticals, Inc.
  6. Summary
    RCKT   US77313F1066

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
46.19(c) 46.18(c) 47.25(c) 46.5(c) 46.74(c) Last
213 290 195 741 309 381 177 463 335 613 Volume
+1.83% -0.02% +2.32% -1.59% +0.52% Change
More quotes
Financials (USD)
Sales 2021 10,0 M - -
Net income 2021 -162 M - -
Net cash position 2021 282 M - -
P/E ratio 2021 -18,0x
Yield 2021 -
Sales 2022 32,5 M - -
Net income 2022 -163 M - -
Net cash position 2022 144 M - -
P/E ratio 2022 -19,0x
Yield 2022 -
Capitalization 2 963 M 2 963 M -
EV / Sales 2021 267x
EV / Sales 2022 86,9x
Nbr of Employees 91
Free-Float 90,9%
More Financials
Company
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the... 
Read more
More about the company
Ratings of Rocket Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ROCKET PHARMACEUTICALS, INC.
05/14ROCKET PHARMACEUTICALS  : Significant Insider Selling Reported in Shares of Rock..
MT
05/13INSIDER TRENDS : Rocket Pharmaceuticals Insider Extends 90-Day Selling Trend
MT
05/13ROCKET PHARMACEUTICALS  : Presents Positive Clinical Data from Fanconi Anemia, L..
BU
05/12ROCKET PHARMACEUTICALS  : —Updated Low Dose Results in RP-A501 Treatment f..
PU
05/11SECTOR UPDATE : Health Care Stocks Ending Tuesday Session Lower, But Biotech Sha..
MT
05/11ROCKET PHARMACEUTICALS  : UBS Adjusts Price Target on Rocket Pharmaceuticals to ..
MT
05/10ROCKET PHARMACEUTICALS  : Management's Discussion and Analysis of Financial Cond..
AQ
05/10ROCKET PHARMACEUTICALS, INC.  : Results of Operations and Financial Condition, R..
AQ
05/10ROCKET PHARMACEUTICALS : Q1 Earnings Snapshot
AQ
05/10ROCKET PHARMACEUTICALS  : Reports First Quarter 2021 Financial Results and Highl..
BU
04/27ROCKET PHARMACEUTICALS  : Announces Upcoming Clinical Data Presentations at the ..
BU
04/27ROCKET PHARMACEUTICALS, INC.  : Other Events (form 8-K)
AQ
04/14ROCKET PHARMACEUTICALS  : Reports Positive Long-Term Clinical Data from RP-L201 ..
BU
04/01INSIDER TRENDS : Insider at Rocket Pharmaceuticals Sale for Taxes Adds to 90-Day..
MT
04/01INSIDER TRENDS : Insider Acquires Rocket Pharmaceuticals Stock Via Option/Deriva..
MT
More news
News in other languages on ROCKET PHARMACEUTICALS, INC.
05/07EQS-ADHOC : HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen ..
04/14USA  : Casa Bianca amplia lista candidati a commissario Fda
More news
Analyst Recommendations on ROCKET PHARMACEUTICALS, INC.
More recommendations
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 70,70 $
Last Close Price 46,74 $
Spread / Highest target 114%
Spread / Average Target 51,3%
Spread / Lowest Target 19,8%
EPS Revisions
Managers and Directors
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Carlos Garcia-Parada Chief Financial Officer
Roderick T. Wong Chairman
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Kinnari Patel Chief Operating Officer & EVP-Development
Sector and Competitors
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.-14.77%2 963
GILEAD SCIENCES, INC.15.57%85 397
WUXI APPTEC CO., LTD.21.14%65 765
REGENERON PHARMACEUTICALS8.38%54 626
BIONTECH SE150.06%52 693
VERTEX PHARMACEUTICALS-20.67%48 918